CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia.

Relapsed/refractory acute myeloid leukemia (AML) patients generally have a dismal prognosis and the treatment remains challenging. Due to the expression of CD7 on 30% AML and not on normal myeloid and erythroid cells, CD7 is an attractive target for immunotherapy of AML. CD7-targeted CAR T-cells had demonstrated encouraging efficacy in xenograft models of AML. We report here on the use of autologous CD7 CAR T-cells in the treatment of a relapsed/refractory AML patient with complex karyotype, TP53 deletion, FLT3-ITD mutation, and SKAP2-RUNX1 fusion gene. Before the CAR T-cell therapy, the patient achieved partial remission with IA regimen and attained complete remission after reinduction therapy (decitabine and venentoclax). Relapse occurred after consolidation (CLAG regimen). Then she failed CLIA regimen combined with venetoclax and exhibited resistance to FLT3 inhibitors. Bone marrow showed 20% blasts (CD7+ 95.6%). A total dose of 5 × 106/kg CD7 CAR T-cells was administered after the decitabine +FC regimen. Seventeen days after CAR T-cells infusion, she achieved morphologic leukemia-free state. The patient developed grade 3 cytokine release syndrome. No severe organ toxicity or immune effector cell-associated neurotoxicity syndrome was observed. In summary, the autologous CD7 CAR T-cell therapy could be considered a potential approach for AML with CD7 expression (NCT04762485).Trial registration Clinical Trials.gov, NCT04762485. Registered on February 21, 2021, prospectively registered.

To the Editor:

Relapsed/refractory (r/r) acute myeloid leukemia (AML) patients generally have a dismal prognosis. Salvage treatments for r/r AML remain particularly challenging in those without targetable mutations or resistant to target agents. Anti CD33, CLL-1, and CD38 chimeric antigen receptor (CAR) T-cell therapy have been applied for the treatment of r/r AML [1-4], which have limitations of “on-target off-tumor” toxicity on normal hematopoietic stem cells or capillary leaking syndrome [5]. CD7 is expressed in approximately 30% AML whereas not expressed in normal myeloid and erythroid cells [6, 7]. Anti-CD7 CAR T-cells demonstrated encouraging efficacy for treating AML in xenograft models [8]. Here, we report the application of autologous CD7 CAR T-cells in an r/r AML patient with complex karyotype, TP53 deletion, FLT3-ITD mutation, and SKAP2-RUNX1 fusion gene.

The patient was a 17-year-old female, diagnosed with AML in May 2021. SNP array revealed a complex karyotype (Additional file 1: Table S1). Molecular biology analysis found ASXL1 (VAF = 6%), FLT3-ITD (AR = 59.4%) gene mutation, and TP53 deletion (proportion = 72%) (Fig. 2d, Additional file 1: Table S2). The patient achieved partial remission with “3 + 7” regimen (IA). Then reinduction therapy (decitabine and venetoclax) was initiated and complete remission (CR) was attained. Afterwards, she received consolidation with the CLAG regimen and sorafenib. Relapse occurred one month after this consolidation. A new SKAP2-RUNX1 fusion gene was identified using targeted transcriptome RNA sequencing (Additional file 1: Table S3). Since she failed reinduction with the CLIA regimen (cladribine, idarubicin, low-dose cytarabine) combined with venetoclax, and gilteritinib [9], she was enrolled in our CD7 CAR T-cell therapy clinical trial (NCT04762485) (Additional file 1: Fig. S2) after informed consent was taken from her parents. Autologous CD7 CAR T-cells were prepared as the recent report [10] and the CD7 CAR configuration was shown in our previous work [11].

Fig. 2

Treatment response of CD7 CAR T-cells infusion. a BM morphology before and after CD7 CAR T-cells infusion; b Change of percentage of blasts and MRD in BM after CD7 CAR T-cells infusion; c Flow cytometry analysis in BM before and after CD7 CAR T-cells infusion; d Change of molecular markers before and after CD7 CAR T-cells infusion

Before the CD7 CAR T-cells infusion, blasts in bone marrow (BM) were 20% (Fig. 2b). Flow cytometry analysis (FCM) demonstrated 12.9% of blasts that had the expression pattern CD34+CD117+CD13+CD33+CD7+CD38+CD45+CD10−CD19−. Of note, the CD7 expression was 95.6% (Fig. 2c). FLT3-ITD and SKAP2-RUNX1 fusion gene remained positive as described in Fig. 2d. Lymphodepletion chemotherapy (decitabine 50 mg/day, day-6 to -3, fludarabine 30 mg/m2/day, day-5 to -3, and cyclophosphamide 300 mg/m2/day, day-5 to -3) was performed. Two days after the chemotherapy, autologous CD7 CAR T-cells were infused at a total dose of 5 × 106/kg by dose escalation within 2 days (d0 1 × 106/kg, d2 4 × 106/kg) (Fig. 1a).

Fig. 1

CD7 CAR T-cell therapy regime and clinical characteristic after infusion. a Schematic of the CD7 CAR T-cell therapy regimen, the total infusion dose of CAR T-cells was 5 × 106/kg for 2 days; b qPCR analysis of the CAR T-cells copies in PB after the infusion. The highest level was on day 14. The patient still has 5,084 CAR-T copies/µg  by day 28; c Change of the temperature and CRP after CD7 CAR T-cells infusion; d Change of cytokines after CD7 CAR T-cells infusion; e Change of the blood cell counts after CD7 CAR T-cells infusion

The patient developed persistent high fever (maximum 39.4 °C, lasting for 12 days) (Fig. 1c), hypotension, grade 4 cytopenia, grade 3 liver dysfunction, and elevated serum IL-6, IL-10, and IFN-γ (Fig. 1d, Additional file 1: Fig. S3) after CAR T-cells infusion. Grade 3 cytokine release syndrome was considered [12, 13]. The toxicities were manageable with a low dose of dexamethasone, norepinephrine, and general supportive care modalities. No signs of severe infections and immune effector cell-associated neurotoxicity syndrome (ICANS) were observed. The patient’s neutropenia persisted for 38 days and the platelets were out of transfusion until 36 days after allogeneic hematopoietic stem cell transplantation (allo-HSCT) (Fig. 1e).

BM aspirates showed no blasts at 17 days after CD7 CAR T-cells infusion and minimal residual disease was 2.5 × 10–4 by FCM (Fig. 2a, b). Karyotype was normal and FISH analysis showed the proportion of TP53 deletion decreased to 9%. The AR of FLT3-ITD mutation decreased to 5.9% and the SKAP2-RUNX1 fusion gene decreased to 3.0%. CAR T-cells in the peripheral blood peaked at 183,945 copies/μg by qPCR on the 14th day after infusion, which were still 5,084 copies/μg on day 28 post CAR T-cell therapy (Fig. 1b). The CD7-positive T and NK cells decreased significantly as detected by FCM after CAR T-cell therapy, but CD7 negative T-cells retained the immune functions necessary for infection prevention (Fig. 2c, Additional file 1: Figs. S4, S5). Two months after the infusion, the patient underwent allo-HSCT and achieved CR without minimal residual disease (Fig. 2d).

Overall, this patient exhibited resistance to chemotherapy, venetoclax and FLT3 inhibitors due to multiple adverse genetic aberrations (TP53 deletion, FLT3-ITD, and rare RUNX1 rearrangement). CD7 CAR T-cell therapy offered an opportunity to reduce tumor burden and bridge to allo-HSCT. Treatment-related toxicity was moderate but manageable. To our knowledge, this is the first case of r/r AML successfully treated with CD7 CAR T-cell therapy. The result suggests that CD7 CAR T-cell therapy is an encouraging approach for the treatment of CD7 positive r/r AML.

Additional file 1: Figure S1. Cytotoxicity and cytokines analysis of the CD7 CAR T-cells. Figure S2. Diagrammatic sketch of the treatments and response. Figure S3. Infusion-related hepatic toxicities. Figure S4. Flow cytometry analysis of the fraction of T-cells and NK cells in the PB after infusion. Figure S5. Flow cytometry of the T-cell fractions in the PB after infusion of CART cells. Table S1. The result of SNP array (Cytoscan 750K/HD) at diagnosis. Table S2. A panel of 222 genes detected by next-generation sequencing. Table S3. A panel of targeted transcriptome RNA sequencing (RNA-seq).